Beta‐Blocker Efficacy in High‐Risk Patients with the Congenital Long‐QT Syndrome Types 1 and 2: Implications for Patient Management
Key result
Beta-blocker therapy was associated with a 67% reduction in cardiac events in high-risk LQT1 males (P=0.02) and a 71% reduction in high-risk LQT2 females (P<0.001).
Why the study?
Does beta-blocker therapy reduce cardiac events in high-risk patients with congenital long-QT syndrome types 1 and 2?
Population
971 patients with congenital long-QT syndrome types 1 and 2 from the International LQTS Registry, followed…
Design
Cohort
Follow-up
from birth through age 40 years
Authors
Discussion
Loading...
Member takes
Implication
Supports beta-blocker consideration in high-risk LQT subgroups; leaves open randomized confirmation and ICD decisions for breakthrough events.
Study Design
Type
Cohort (n=971)
Multicenter
Yes
Structured PICO
Does beta-blocker therapy reduce cardiac events in high-risk patients with congenital long-QT syndrome types 1 and 2?
P
Population
971 patients with congenital long-QT syndrome types 1 and 2 from the International LQTS Registry, evaluated from birth through age 40 years.
E
Exposure
Beta-blocker therapy
O
Outcome
Cardiac events (composite of syncope, aborted cardiac arrest [ACA], or sudden cardiac death [SCD])composite
Beta-blockers significantly reduce cardiac events in high-risk LQT1 and LQT2 patients, though those who experience syncope while on therapy remain at high risk for aborted cardiac arrest or sudden cardiac death and should be considered for primary defibrillator therapy.
Cite This Study
Goldenberg et al. (2010) conducted a cohort in congenital long-QT syndrome (LQTS) types 1 and 2 (n=971). Beta-blocker therapy vs. No beta-blocker therapy was evaluated on cardiac events (comprising syncope, aborted cardiac arrest [ACA] or sudden cardiac death [SCD]). Beta-blocker therapy was associated with a 67% reduction in cardiac events in high-risk LQT1 males (P=0.02) and a 71% reduction in high-risk LQT2 females (P<0.001).